Gilead Sciences (GILD) PEG Ratio: History & Chart

Gilead Sciences, Inc. (GILD)GILDGilead Sciences, Inc.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA

17,000 employees

www.gilead.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Daniel O'Day

View full financials

GILD PEG Ratio Metrics

PEG RATIO

0.01

PEG RATIO AVG TTM

N/A

PEG RATIO AVG 3Y

0.38

PEG RATIO AVG 5Y

0.25

PEG RATIO AVG 10Y

2.96

PEG RATIO AVG 15Y

2.24

PEG RATIO AVG 20Y

0.50

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

-97.33%

CURRENT VS 5Y AVG

-96.00%

CURRENT VS 10Y AVG

-99.66%

CURRENT VS 15Y AVG

-99.55%

CURRENT VS 20Y AVG

-98.00%

SECTOR MEDIAN · HEALTHCARE

1.82

median of 49 covered companies

CURRENT VS SECTOR MEDIAN

-99.45%

vs the sector median at left

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Gilead Sciences, Inc. (GILD)	$161.66B	0.01	N/A	0.38	0.25
Pfizer Inc. (PFE)vs ›	$142.54B	N/A	0.07	0.13	0.16
Abbott Laboratories (ABT)vs ›	$184.11B	4.13	0.11	0.36	0.88
Danaher Corporation (DHR)vs ›	$137.13B	86.58	1.24	1.13	1.93
Bristol-Myers Squibb Company (BMY)vs ›	$133.37B	1.53	0.24	0.24	0.18
CVS Health Corp. (CVS)vs ›	$133.25B	N/A	0.13	1.20	1.17
AstraZeneca PLC (AZN)vs ›	$131.47B	0.29	0.52	0.32	0.28
Stryker Corporation (SYK)vs ›	$124.86B	5.16	5.16	2.81	2.63
Intuitive Surgical, Inc. (ISRG)vs ›	$124.82B	3.17	3.02	2.60	2.27
Vertex Pharmaceuticals Incorporated (VRTX)vs ›	$121.09B	3.46	2.58	1.90	1.47

NAME

MARKET CAP

PEG RATIO

TTM

Gilead Sciences, Inc. (GILD)

$161.66B

0.01

N/A

0.38

0.25

Pfizer Inc. (PFE)vs ›

$142.54B

N/A

0.07

0.13

0.16

Abbott Laboratories (ABT)vs ›

$184.11B

4.13

0.11

0.36

0.88

Danaher Corporation (DHR)vs ›

$137.13B

86.58

1.24

1.13

1.93

Bristol-Myers Squibb Company (BMY)vs ›

$133.37B

1.53

0.24

0.18

CVS Health Corp. (CVS)vs ›

$133.25B

N/A

0.13

1.20

1.17

AstraZeneca PLC (AZN)vs ›

$131.47B

0.29

0.52

0.32

0.28

Stryker Corporation (SYK)vs ›

$124.86B

5.16

2.81

2.63

Intuitive Surgical, Inc. (ISRG)vs ›

$124.82B

3.17

3.02

2.60

2.27

Vertex Pharmaceuticals Incorporated (VRTX)vs ›

$121.09B

3.46

2.58

1.90

1.47

PEG Ratio FAQ

What is the PEG ratio for Gilead Sciences, Inc. (GILD)?

The PEG ratio for GILD stock is 0.01.

Is Gilead Sciences, Inc.'s PEG ratio high or low?

The PEG ratio of 0.01 is 96% below its 4-year average of 0.25, near the low end of its 4-year range (0.00–0.74).

What is the 3Y average PEG ratio for Gilead Sciences, Inc. (GILD)?

The 3Y average PEG ratio for GILD stock is 0.38.

What is the 5Y average PEG ratio for Gilead Sciences, Inc. (GILD)?

The 5Y average PEG ratio for GILD stock is 0.25.

What is the 10Y average PEG ratio for Gilead Sciences, Inc. (GILD)?

The 10Y average PEG ratio for GILD stock is 2.96.

What is the 15Y average PEG ratio for Gilead Sciences, Inc. (GILD)?

The 15Y average PEG ratio for GILD stock is 2.24.

What is the 20Y average PEG ratio for Gilead Sciences, Inc. (GILD)?

The 20Y average PEG ratio for GILD stock is 0.50.

DATE	PEG RATIO
2025-12-31	0.01
2023-12-31	0.74
2021-12-31	0.00
2019-12-31	16.09
2018-12-31	0.80
2015-12-31	0.15
2014-12-31	0.04
2013-12-31	2.13
2011-12-31	1.75
2010-12-31	0.65
2009-12-31	0.44
2008-12-31	0.93
2006-12-31	0.10
2005-12-31	0.40
2003-12-31	0.83
2002-12-31	2.84
2000-12-31	3.39
1996-12-31	0.81

DATE

PEG RATIO

2025-12-31

0.01

2023-12-31

0.74

2021-12-31

0.00

2019-12-31

16.09

2018-12-31

0.80

2015-12-31

0.15

2014-12-31

0.04

2013-12-31

2.13

2011-12-31

1.75

2010-12-31

0.65

2009-12-31

0.44

2008-12-31

0.93

2006-12-31

0.10

2005-12-31

0.40

2003-12-31

0.83

2002-12-31

2.84

2000-12-31

3.39

1996-12-31

0.81

PEG Ratio: 0.01

GILD PEG Ratio Chart

GILD Average PEG Ratio Chart

GILD Current vs Average PEG Ratio Chart

GILD PEG Ratio Metrics

GILD Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

PEG Ratio FAQ

GILD PEG Ratio History

Related Metrics